Search

Your search keyword '"Crain, Marilyn"' showing total 4 results
Start Over Author "Crain, Marilyn" Topic adult
4 results on '"Crain, Marilyn"'

1. Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol.

Author

Jao, Jennifer, Kacanek, Deborah, Williams, Paige L, Geffner, Mitchell E, Livingston, Elizabeth G, Sperling, Rhoda S, Patel, Kunjal, Bardeguez, Arlene D, Burchett, Sandra K, Chakhtoura, Nahida, Scott, Gwendolyn B, Van Dyke, Russell B, Abrams, Elaine J, Yogev, Ram, Sanders, Margaret Ann, Malee, Kathleen, Hunter, Scott, Shearer, William, Paul, Mary, Cooper, Norma, Harris, Lynnette, Purswani, Murli, Stuard, Emma, Cintron, Anna, Puga, Ana, Cooley, Dia, Garvie, Patricia A, Blood, James, Borkowsky, William, Deygoo, Sandra, Vasserman, Marsha, Dieudonne, Arry, Bettica, Linda, Knapp, Katherine, Allison, Kim, Wilkins, Megan, Acevedo-Flores, Midnela, Angeli-Nieves, Lourdes, Olivera, Vivian, Kohlhoff, Stephan, Dennie, Ava, Bewley, Susan, Dyke, Russell Van, Craig, Karen, Sirois, Patricia, Crain, Marilyn, Hickman, Paige, Marullo, Dan, Spector, Stephen A, Norris, Kim, Nichols, Sharon, McFarland, Elizabeth, Chambers, Carrie, Wallace, Jenna, Barr, Emily, Rathore, Mobeen, Stowers, Kristi, Mahmoudi, Saniyyah, Usitalo, Ann, Hayani, Karen, Rich, Kenneth, Richardson, Lourdes, Smith, Renee, Mitchell, Charles, Dominguez, Sady, Florez, Claudia, Frederick, Toni, Davtyan, Mariam, Morales-Avendano, Guadalupe, Rodriguez, Zoe M, Heyer, Ibet, Trifilio, Nydia Scalley, Scott, GB, Tuomala, R, Smith, E, Watts, H, Oden, KM, Huo, Y, Patel, K, Barr, EA, Bardeguez, A, Burchett, SK, Livingston, E, Stek, AM, Basar, MT, Hernandez, A, Jennings, A, Cressey, TR, Bryant, J, Tuomala, Ruth, Smith, Elizabeth, Oden, KaSaundra M, Leister, Erin, Shapiro, David E, Barr, Emily A, Wara, Diane W, Bardeguez, Arlene, and Guiterrez, Jenny

Subjects
Prevention, Pediatric Research Initiative, Clinical Research, Infant Mortality, Perinatal Period - Conditions Originating in Perinatal Period, Pediatric, Infectious Diseases, Preterm, Low Birth Weight and Health of the Newborn, Reproductive health and childbirth, Good Health and Well Being, Adult, Birth Weight, CD4 Lymphocyte Count, Female, HIV Infections, Humans, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infectious Disease Transmission, Vertical, Male, Pregnancy, Pregnancy Complications, Infectious, Premature Birth, Prospective Studies, United States, Young Adult, Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol, Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol, birth weight, perinatal HIV infection, pregnancy, preterm delivery, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundPregnancy outcomes of perinatally human immunodeficiency virus-infected women (PHIV) are poorly defined.MethodsWe compared preterm delivery and birth weight (BW) outcomes (low BW [LBW],

Published
2017

2. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia

Author

Melvin, Ann J, Montepiedra, Grace, Aaron, Lisa, Meyer, William A, Spiegel, Hans M, Borkowsky, William, Abzug, Mark J, Best, Brookie M, Crain, Marilyn J, Borum, Peggy R, Graham, Bobbie, Anthony, Patricia, Shin, Katherine, and Siberry, George K

Subjects
Paediatrics, Biomedical and Clinical Sciences, Atherosclerosis, Prevention, Clinical Research, Pediatric, HIV/AIDS, Infectious Diseases, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Anti-HIV Agents, Atorvastatin, C-Reactive Protein, Child, Female, HIV Infections, Humans, Hyperlipidemias, Male, Young Adult, HIV, children, atorvastatin, P1063 Study Team, Paediatrics and Reproductive Medicine, Public Health and Health Services, Pediatrics, Clinical sciences
Abstract

BackgroundHuman immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of statins in this population.MethodsHIV-infected youth 10 to

Published
2017

3. Growth at age two in HIV-exposed uninfected children in the US by trimester of maternal antiretroviral initiation

Author

Jacobson, Denise L., Patel, Kunjal, Williams, Paige L., Geffner, Mitchell E., Siberry, George K., Dimeglio, Linda A., Crain, Marilyn J., Mirza, Ayesha, Chen, Janet S., McFarland, Elizabeth J., Kacanek, Deborah, Silio, Margarita, Rich, Kenneth, Borkowsky, William, Van Dyke, Russell B., and Miller, Tracie L.

Subjects
Adult, Body Weight, Mothers, HIV Infections, Article, Body Height, Time-to-Treatment, Child Development, Anti-Retroviral Agents, Maternal Exposure, Child, Preschool, Humans, Female, Prospective Studies
Abstract

Abnormal childhood growth may affect future health. Maternal tenofovir (TFV) use was associated with lower body length and head circumference at 1 year of age in HIV-exposed uninfected (HEU) US children.We studied 509 HEU children in the US-based Surveillance Monitoring of Antiretroviral Therapy Toxicities cohort whose HIV-infected mothers were not using antiretrovirals at the last menstrual period and began combination antiretroviral therapy (cART) in pregnancy (cART initiators). We examined adjusted associations between antiretrovirals and Centers for Disease Control 2000 growth Z scores at 2 years of age within trimester of cART initiation: weight (weight Z score), length (length Z score), weight-for-length [weight-for-length Z score (WFLZ)], triceps skinfold Z score (TSFZ) and head circumference (head circumference Z score).Mothers mean age was 28.6 years; 57% were black non-Hispanic and 19% delivered at37 weeks gestation. At 2 years, mean weight Z score, length Z score, WFLZ and head circumference Z score were above average (P0.05), whereas TSFZ (P = 0.57) did not differ from average. WFLZ was1.64 standard deviation (SD) (95th percentile) in 13%. Among children of first-trimester cART initiators, TFV+emtricitabine-exposed children had slightly higher mean WFLZ (0.45 SD; 95% confidence interval: -0.10 to 1.00) and lower TSFZ (-0.55 SD; 95% confidence interval: -1.07 to -0.02) compared with zidovudine+lamivudine-exposed children. TSFZ was lower in those exposed to boosted protease inhibitors. In contrast, growth in children of second trimester cART initiators did not differ by antiretroviral exposures.Growth was above average in HEU; 13% were obese. Maternal TFV use was not associated with lower length or head circumference at 2 years of age, as hypothesized, but may be related to greater weight among those exposed to cART early in pregnancy.

Published
2017

4. Antiretroviral Exposure During Pregnancy and Adverse Outcomes in HIV-exposed Uninfected Infants and Children Using a Trigger-based Design: The SMARTT Study

Author

WILLIAMS, Paige L., HAZRA, Rohan, VAN DYKE, Russell B., YILDIRIM, Cenk, CRAIN, Marilyn J., SEAGE, George R., CIVITELLO, Lucy, ELLIS, Angela, BUTLER, Laurie, and RICH, Kenneth

Subjects
Adult, Male, Drug-Related Side Effects and Adverse Reactions, Infant, Newborn, Infant, HIV Infections, Article, United States, Young Adult, Anti-Retroviral Agents, Maternal Exposure, Pregnancy, Child, Preschool, Humans, Female, Prospective Studies, Pregnancy Complications, Infectious, Child, Zidovudine
Abstract

To evaluate the safety of in-utero antiretroviral exposure in children born to mothers with HIV, using a trigger-based design.The Surveillance Monitoring of ART Toxicities Study is a prospective cohort study conducted at 22 US sites to evaluate safety of in-utero antiretroviral drug exposure in HIV-uninfected children born to HIV-infected mothers. Children meeting predefined clinical or laboratory thresholds have more intensive evaluations to determine whether they meet criteria for adverse events.Adverse event "cases" were defined for the following domains: growth, hearing, language, neurology, neurodevelopment, metabolic, hematologic/clinical chemistry and blood lactate. We used adjusted log-binomial models to calculate relative risks (RR) of case status overall and within individual domains for various antiretroviral exposures during pregnancy.Among 2680 youth enrolled between 2007 and 2012 (48% female, 66% black, 33% Hispanic), 48% met a trigger and 25% were defined as a case in at least one domain. Language (13.2%) and metabolic (11.4%) cases were most common. After adjustment for birth cohort and other factors, there was no association of any antiretroviral regimen, drug class, or individual drug with meeting overall case criteria (case in any domain). Within individual domains, zidovudine (74% exposed) was associated with increased risk of metabolic case [RR = 1.69, 95%confidence interval (CI) 1.08-2.64] and didanosine plus stavudine (1% exposed) with increased risk of both neurodevelopmental (RR = 12.40, 95%CI 5.29-29.08) and language (RR = 4.84, 95%CI 1.14-20.51) cases.Our findings support current recommendations for combination antiretroviral therapy during pregnancy, although higher risk of metabolic disorder with zidovudine exposure warrants further study.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results